State Street
NVCT icon

State Street’s Nuvectis Pharma NVCT Stock Holding History

State Street’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.56M Buy
248,198
+81,682
+49% +$914K ﹤0.01% 3055
2026
Q1 		$1.29M Buy
166,516
+11,850
+8% +$102K ﹤0.01% 3429
2025
Q4 		$1.17M Buy
154,666
+17,950
+13% +$117K ﹤0.01% 3490
2025
Q3 		$823K Buy
136,716
+23,137
+20% +$159K ﹤0.01% 3551
2025
Q2 		$848K Buy
113,579
+85,829
+309% +$778K ﹤0.01% 3519
2025
Q1 		$271K Buy
27,750
+5,750
+26% +$41.4K ﹤0.01% 3753
2024
Q4 		$119K Buy
22,000
+6,700
+44% +$42K ﹤0.01% 3960
2024
Q3 		$96.2K Hold
15,300
– – ﹤0.01% 3985
2024
Q2 		$96.8K Sell
15,300
-114,079
-88% -$775K ﹤0.01% 4022
2024
Q1 		$1.06M Buy
129,379
+11,100
+9% +$94.4K ﹤0.01% 3457
2023
Q4 		$986K Buy
118,279
+10,157
+9% +$90.6K ﹤0.01% 3484
2023
Q3 		$1.39M Buy
108,122
+2,882
+3% +$41.8K ﹤0.01% 3445
2023
Q2 		$1.68M Buy
105,240
+91,840
+685% +$1.47M ﹤0.01% 3465
2023
Q1 		$176K Buy
13,400
+1,700
+15% +$17.2K ﹤0.01% 4123
2022
Q4 		$87.9K Hold
11,700
– – ﹤0.01% 4408
2022
Q3 		$83K Hold
11,700
– – ﹤0.01% 4528
2022
Q2 		$131K Buy
+11,700
New +$145K ﹤0.01% 4395

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

State Street's NVCT Position: Q2 2026 in Review

State Street increased its Nuvectis Pharma (NVCT) stake by 49% in Q2 2026, buying an estimated $914K and bringing the position to 248,198 shares worth $4.56M. The position accounts for ﹤0.01% of the portfolio, ranked #3055.

State Street first reported a position in NVCT in Q2 2022 and has held it in 17 quarters since. 82 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • State Street held 248,198 shares of Nuvectis Pharma worth $4.56M as of Q2 2026.
  • State Street bought 81,682 Nuvectis Pharma shares in Q2 2026, an estimated $914K.
  • Nuvectis Pharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3055 holding.
  • State Street first reported a position in Nuvectis Pharma in Q2 2022 and has held it in 17 quarters since.
  • 82 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.